Initial public offerings (IPO) are a special type of fund raising. For biotech companies it’s even more special as they are rarely profitable and do not have a commercial track record. How do you present biotech companies aiming for an IPO to investors? What is the role of legal advisors, auditors, and banks in this process? What is needed to conduct a successful IPO?
Even if you are not planning to prepare for an IPO, it is always good to understand the process.

In this workshop, you will get first-hand information from industry experts and learn from people with real-life experiences who already went through the challenges of a biotech IPO:

Chandra Leo, Partner, HBM Partners
Fabian Gerber, Senior Relationship Manager, SIX
Viktoriya Lombardo, Director Audit & Assurance, Deloitte AG
Karina Chavez, Director Audit & Assurance, Deloitte AG
Boris Rausch, Director, Credit Suisse IB Coverage Team (Focus Biotech und Life Sciences)
Alex Herrmann, Equity Capital Markets Switzerland, Credit Suisse

The workshop is ideal for

  • CEOs and CFOs of biotech companies
  • Investors, who invest in biotech companies
  • Anyone interested in understanding IPOs of biotechs

SIX Swiss Exchange provides complimentary coffee, tea, cold drinks and Gipfeli. A light lunch follows the event. Participation is free of charge but you have to register, as seats are limited. In case of over-subscription participants from Swiss biotech companies will be given priority.

  • January 27, 2023 @ 9:00 am
  • Zürich
Event starts in
  • 00

  • 00

  • 00


Pfingstweidstrasse 110, Zürich, Switzerland